"Inflammation Mediators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC).
| Descriptor ID |
D018836
|
| MeSH Number(s) |
D23.469
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Inflammation Mediators".
Below are MeSH descriptors whose meaning is more specific than "Inflammation Mediators".
This graph shows the total number of publications written about "Inflammation Mediators" by people in this website by year, and whether "Inflammation Mediators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 3 | 2 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 7 | 8 |
| 2009 | 6 | 5 | 11 |
| 2010 | 3 | 3 | 6 |
| 2011 | 4 | 8 | 12 |
| 2012 | 4 | 5 | 9 |
| 2013 | 7 | 13 | 20 |
| 2014 | 4 | 11 | 15 |
| 2015 | 1 | 9 | 10 |
| 2016 | 3 | 8 | 11 |
| 2017 | 1 | 13 | 14 |
| 2018 | 3 | 3 | 6 |
| 2019 | 5 | 5 | 10 |
| 2020 | 4 | 4 | 8 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 1 | 1 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Inflammation Mediators" by people in Profiles.
-
A mechanistic LNK between inflammation and atrial fibrillation? Cardiovasc Res. 2024 Jul 02; 120(8):814-816.
-
Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities. Circ Res. 2024 Jun 07; 134(12):1718-1751.
-
Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment. Vasc Med. 2024 Aug; 29(4):369-380.
-
Circulating Proteome Analysis Identifies Reduced Inflammation After Initiation of Hemodynamic Support with Either Veno-Arterial Extracorporeal Membrane Oxygenation or Impella in Patients with Cardiogenic Shock. J Cardiovasc Transl Res. 2024 08; 17(4):935-945.
-
Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 01; 138(3):664-675.
-
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 03 01; 50(3):398-409.
-
Myeloid cell TBK1 restricts inflammatory responses. Proc Natl Acad Sci U S A. 2022 01 25; 119(4).
-
Cardioprotective Effects of Oroxylum indicum Extract Against Doxorubicin and Cyclophosphamide-Induced Cardiotoxicity. Cardiovasc Toxicol. 2022 01; 22(1):67-77.
-
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22.
-
Erythrocyte adenosine A2B receptor prevents cognitive and auditory dysfunction by promoting hypoxic and metabolic reprogramming. PLoS Biol. 2021 06; 19(6):e3001239.